Document Detail


Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.
MedLine Citation:
PMID:  6301090     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The specific thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 13-azaprostanoic acid (13-APA) reverses platelet aggregation stimulated by TXA2/PGH2 and the prostaglandin endoperoxide analog U46619. The present report demonstrates that the deaggregatory properties of 13-APA are potentiated by prostacyclin (PGI2). Human platelet-rich plasma was aggregated with U46619. Deaggregation was induced 2 min subsequent to the addition of the aggregating agent. Concentrations of 13-APA or PGI2 which induced 20 percent deaggregation were determined. Simultaneous addition of half of these concentrations resulted in 60 percent deaggregation, demonstrating that the observed response was supraadditive. Measurement of cyclic adenosine 3':5' monophosphate (cAMP) in resting or deaggregating platelets demonstrated that 13-APA itself did not stimulate cAMP production nor did 13-APA facilitate PGI2-induced increases in cAMP. In separate studies PGI2 and 13-APA were added to PRP prior to the induction of aggregation by U46619. Under these conditions, additive inhibition of aggregation was observed. Thus, it is clear that the pharmacological interaction between PGI2 and 13-APA depends upon the relative state of platelet activation.
Authors:
L V Parise; D L Venton; G C Le Breton
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Thrombosis research     Volume:  28     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1982 Dec 
Date Detail:
Created Date:  1983-05-05     Completed Date:  1983-05-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  721-30     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Adenosine Diphosphate / pharmacology
Blood Platelets / metabolism
Cyclic AMP / biosynthesis
Drug Synergism
Epoprostenol / pharmacology*
Fatty Acids / pharmacology*
Humans
Platelet Aggregation / drug effects*
Prostaglandin Endoperoxides, Synthetic / antagonists & inhibitors*
Prostaglandins / pharmacology*
Prostanoic Acids / pharmacology*
Grant Support
ID/Acronym/Agency:
HL 24530/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Fatty Acids; 0/Prostaglandin Endoperoxides, Synthetic; 0/Prostaglandins; 0/Prostanoic Acids; 35121-78-9/Epoprostenol; 58-64-0/Adenosine Diphosphate; 60-92-4/Cyclic AMP; 71629-07-7/13-azaprostanoic acid; 76898-47-0/15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glioblastoma of the cerebellum. Computed tomographic and pathologic considerations.
Next Document:  Improvement of the periodate-borohydride surface-labeling method for human blood platelets.